Eva Estébanez-Perpiñá Selected Research

EPI 001

1/2016

EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eva Estébanez-Perpiñá Research Topics

Disease

9	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 10/2007
6	Neoplasms (Cancer) 01/2021 - 03/2005
4	Androgen-Insensitivity Syndrome (Testicular Feminization) 01/2019 - 10/2007
1	Glucocorticoid Receptor Deficiency 09/2021
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Male Infertility (Male Sterility) 01/2017
1	Disease Progression 01/2016
1	Intellectual Disability (Idiocy) 01/2012
1	Glioblastoma (Glioblastoma Multiforme) 01/2012

Drug/Important Bio-Agent (IBA)

10	Androgen Receptors (Androgen Receptor)IBA 01/2021 - 03/2005
3	Pharmaceutical PreparationsIBA 01/2021 - 01/2012
3	Hormones (Hormone)IBA 01/2021 - 03/2005
3	Transcription Factors (Transcription Factor)IBA 01/2018 - 01/2012
3	AndrogensIBA 01/2016 - 03/2005
2	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 09/2021 - 01/2021
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2021 - 01/2016
2	LigandsIBA 01/2021 - 03/2014
2	Thyroid Hormone Receptors (Thyroid Hormone Receptor)IBA 01/2021 - 01/2019
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2021
1	Liver X ReceptorsIBA 01/2021
1	LipidsIBA 01/2021
1	Estrogen ReceptorsIBA 01/2021
1	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 01/2021
1	Retinoid X Receptors (Retinoid X Receptor)IBA 01/2021
1	SolutionsIBA 01/2016
1	EPI 001IBA 01/2016
1	Oncogene Proteins (Oncogene Protein)IBA 01/2012
1	Furylfuramide (AF2)IBA 10/2007
1	Androgen Antagonists (Antiandrogens)IBA 10/2007

Therapy/Procedure

2	Castration 01/2018 - 01/2016
2	Therapeutics 01/2016 - 10/2007